Die multimodale Therapie des Analkarzinoms

Abstract

Mitomycin a significant difference in colostomy free survival for the Mitomycin containing regimen was observed. There was a trend for survival benefit in favour of Mitomycin and less deaths attributed to tumor progression. After a treatment dose of 45 Gy in node negative patients and 50.4 Gy in node positive patients a salvage with additional radiotherapy of 9 Gy with concomitant continuous Fluororuracil and DDP 100 mg/m 2 day 2 was possible in half of the patients. Some of the remaining open questions are adressed in on-going studies.